ProSomnus will commence trading on the Nasdaq ... the Company to increase manufacturing capacity four-fold for its Oral Appliance Therapy (“OAT”) devices to meet the rising demand of providers ...

Growth is driven by rising lifestyle-related disorders like diabetes and obesity, spurring obstructive sleep apnea. The home ...

Other initiatives will include investments in next-gen manufacturing techniques, as well as efforts to raise public awareness of OSA and the value-added features of the ProSomnus Oral Appliance ...

The ProSomnus EVO is an alternative to legacy oral devices and CPAP machines, and can result in more effective treatment and superior patient compliance. It repositions and stabilizes the jaw ...

ProSomnus is honored to partner with Lovell to expand access to Precision Oral Appliance Therapy for the millions of Veterans with Obstructive Sleep Apnea.” — Len Liptak, CEO, ProSomnus Sleep ...

oxygen monitoring provides ongoing assessment of the efficacy of oral appliance therapy.” ProSomnus (NASDAQ: OSA) is the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea ...

The global anti-snoring devices market, valued at US$ 0.83 billion in 2023, is forecasted to grow at a robust CAGR of 9.8%, ...

ProSomnus Inc OSA has completed enrollment in the FLOSAT study, a head-to-head, crossover study comparing the effectiveness of precision oral appliance therapy (OAT) as first-line treatment versus ...

About ProSomnus ProSomnus is the first manufacturer of precision, mass-customized Precision Oral Appliance Therapy devices to treat OSA, which affects over 74 million Americans and is associated ...